Protagonist Therapeutics Financial Statements
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics revenue and earnings
In fiscal 2025, Protagonist Therapeutics generated $46.0 million in revenue, down 89.4% from fiscal 2024, its first annual decline since 2022. Protagonist Therapeutics reported a net loss of $130.1 million, compared with net income of $275.2 million a year earlier. Operating margin was -343.6%.
Diluted earnings per share came in at -$2.05, down from $4.23. Over the last 5 fiscal years, PTGX's revenue has grown at a 10.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.02M | 434.43M | 60.00M | 26.58M | 27.36M | 28.63M | 231.00K | 30.93M | 20.06M | — |
| Revenue growth (YoY) | -89.41% | +624.05% | +125.73% | -2.84% | -4.44% | +12293.07% | -99.25% | +54.14% | — | — |
| Operating Expenses | 204.14M | 181.59M | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M |
| Research & Development | 159.29M | 138.13M | 120.16M | 126.22M | 126.01M | 74.51M | 65.00M | 59.50M | 46.18M | 25.70M |
| Operating Income | -158.13M | 252.84M | -93.65M | -131.37M | -125.84M | -64.52M | -80.52M | -42.27M | -37.90M | -32.67M |
| Interest Expense | — | — | — | — | — | 598.00K | 169.00K | — | — | — |
| Other Income (Expense) | 27.00K | 250.00K | -201.00K | -80.00K | -149.00K | -46.00K | -1.00K | -20.00K | -8.00K | -34.00K |
| Pretax Income | -129.31M | 279.41M | -78.95M | -127.39M | -125.55M | -64.84M | -77.88M | -39.72M | -36.96M | -37.18M |
| Income Tax | 838.00K | 4.22M | 0 | 0 | 0 | 1.30M | -691.00K | -799.00K | 0 | 0 |
| Net Income | -130.15M | 275.19M | -78.95M | -127.39M | -125.55M | -66.15M | -77.19M | -38.92M | -36.96M | -37.18M |
| Net Income growth (YoY) | -147.29% | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.05 | 4.47 | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 | -1.74 | -2.09 | -5.80 |
| EPS (Diluted) | -2.05 | 4.23 | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 | -1.74 | -2.09 | -5.80 |
| Shares Outstanding (Basic) | 63.57M | 61.57M | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M |
| Shares Outstanding (Diluted) | 63.57M | 65.08M | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M |
| EBITDA | -156.85M | 253.67M | -92.67M | -130.34M | -125.03M | -63.57M | -79.79M | -41.74M | -37.49M | -32.35M |
| Operating Margin | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% | -225.36% | -34857.58% | -136.68% | -188.89% | — |
| Net Margin | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% | -231.07% | -33414.29% | -125.87% | -184.20% | — |
This table shows 10 annual periods of Protagonist Therapeutics's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PTGX's reporting calendar. What is a income statement?